301 related articles for article (PubMed ID: 21421599)
1. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Steffel J; Braunwald E
Eur Heart J; 2011 Aug; 32(16):1968-76, 1976a. PubMed ID: 21421599
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
4. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
6. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
8. New oral anticoagulants in elderly patients.
Barco S; Cheung YW; Eikelboom JW; Coppens M
Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
[TBL] [Abstract][Full Text] [Related]
9. New oral anticoagulants in the ED setting: a review.
Pollack CV
Am J Emerg Med; 2012 Nov; 30(9):2046-54. PubMed ID: 22795419
[TBL] [Abstract][Full Text] [Related]
10. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
11. Implications of new anticoagulants in primary practice.
Perez A; Eraso LH; Merli GJ
Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
14. [Novel anticoagulants for stroke prevention in atrial fibrillation].
Baumhäkel M; Schirmer SH; Böhm M
Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013
[TBL] [Abstract][Full Text] [Related]
15. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Chatterjee S; Sardar P; Giri JS; Ghosh J; Mukherjee D
Mayo Clin Proc; 2014 Jul; 89(7):896-907. PubMed ID: 24996233
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
18. Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Toth PP
Postgrad Med; 2013 May; 125(3):155-61. PubMed ID: 23748516
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
20. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
